<DOC>
	<DOCNO>NCT01220973</DOCNO>
	<brief_summary>RATIONALE : Atorvastatin calcium celecoxib may stop growth tumor cell block enzymes need cell growth . Giving atorvastatin calcium together celecoxib may kill tumor cell . PURPOSE : This phase II trial study well give atorvastatin calcium together celecoxib work treat patient rise PSA level local therapy prostate cancer .</brief_summary>
	<brief_title>Atorvastatin Calcium Celecoxib Treating Patients With Rising PSA Levels After Local Therapy Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine effect biological activity , assess prostate-specific antigen ( PSA ) response , atorvastatin calcium celecoxib patient D0 prostate cancer . Secondary - To document safety feasibility atorvastatin calcium celecoxib patient early-stage prostate cancer . - To evaluate effect combination atorvastatin calcium celecoxib nuclear factor-kB ( NFkB ) , extracellular signal-regulated kinase ( ERK ) , prostaglandin E2 ( PGE2 ) , IL6 peripheral blood mononuclear cell ( PBMC ) . OUTLINE : This multicenter study . Patients receive oral atorvastatin calcium daily oral celecoxib twice daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients may undergo blood sample collection baseline completion study therapy correlative study . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Stage D0 disease Tumor originally diagnose limited prostate rise prostatespecific antigen ( PSA ) definitive local therapy Must undergone local treatment via prostatectomy radiotherapy PSA value must ≥ 0.2 ng/mL determine 2 measurement , ≥ 1 month apart ≥ 6 month prostatectomy PSA value must ≥ 2.0 ng/mL determine 2 measurement , ≥ 1 month apart ≥ 6 month radiotherapy The first two PSA value along third value must rise ( i.e. , must overall rise trajectory , third value lower first value ) No metastatic disease baseline bone scan CT scan abdomen and/or pelvis PATIENT CHARACTERISTICS : Life expectancy ≥ 6 month ECOG performance status 02 WBC ≥ 3,500/µL ANC ≥ 1,500/µL Platelet count &gt; 100,000/µL Hemoglobin &gt; 10 g/dL Serum creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 50 mL/min Total bilirubin normal SGOT and/or SGPT normal No serious concomitant systemic disorder , discretion investigator , would compromise safety patient compromise patient 's ability complete study No second primary malignancy within past 5 year except adequately treat situ carcinoma ( e.g. , nonmelanomatous carcinoma skin ) malignancy evidence recurrence No active clinically significant infection require antibiotic No history coronary artery disease No myocardial infarction within past 6 month No sulfa allergy No history gastrointestinal bleeding PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior hormoneablative treatment Prior neoadjuvant hormoneablative therapy allow provide complete ≥ 3 month ago More 4 week since prior herbal product hormonal activity soy , saw palmetto , PCSPES No prior concurrent nonsteroidal antiinflammatory drug ( NSAIDS ) 7 consecutive day No COX2 inhibitor and/or statin within past 6 month No concurrent warfarin anticoagulant , calcitriol , fibric acid derivative , lipidmodifying dos niacin , strong cytochrome P450 3A4 inhibitor ( e.g. , cyclosporine , erythromycin , clarithromycin , azole antifungal ) inducer ( e.g. , St John wort ) No concurrent anticancer agent therapy include chemotherapy , hormonal therapy , radiotherapy , experimental therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>